Effects of quercetin supplementation on cardiovascular risk factors and inflammatory biomarkers in patients with type 2 diabetes

Journal of Isfahan Medical School

Volumn 30, Issue 215, 2013, Pages 2039-2051

  Zahedi, Maryam ^a   Ghiasvand, Reza ^a   Feizi, Awat ^a   Asgari, Gholam Reza ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Blood pressure; Inflammatory biomarkers; Lipid profile; Quercetin

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; QUERCETIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LIPID ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE;

EID: 84940320701     PISSN: 10277595     EISSN: 1735854X     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Aghamolaei T, Eftekhar H, Mohammad K, Nakhjavani M, Shojaeizadeh D, Ghofranipour F, et al. Effects of a health education program on behavior, HbA 1c and health-related quality of life in diabetic patients. Acta Medica Iranica 2005; 43(2): 89-94.
2. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22(2): 233-40.
3. World Health Organization. Diet, physical activity and health. Geneva, Switzerland: World Health Organization; 2001.
4. Demonstration projects for the integrated prevention and control of noncommunicable diseases (INTERHEALTH programme): epidemiological background and rationale. INTERHEALTH Sterring Committee. World Health Stat Q 1991; 44(2): 48-54.
5. Naghavi M. Mortality in ten provinces of Iran. Tehran, Iran: Deputy for Health, Ministry of Health and Medical Education; 2002. p. 53-106.[In Persian].
6. Mazloom Z, Hejazi N, Ekramzadeh M, Zare H. Anthropometric measurements and hypertension in cardiovascular disease patients. Proceeding of 10 th Iranian Nutrition Congress; 2008 Oct 27-29;Tehran, Iran.
7. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005; 25(1): 29-38.
8. Hsueh WA, Law RE. Cardiovascular risk continuum: implications of insulin resistance and diabetes. Am J Med 1998; 105(1A): 4S-14S.
9. Devaraj S, Dasu MR, Jialal I. Diabetes is a proinflammatory state: a translational perspective. Expert Rev Endocrinol Metab 2010; 5(1): 19-28.
10. Dengel DR, Pratley RE, Hagberg JM, Rogus EM, Goldberg AP. Distinct effects of aerobic exercise training and weight loss on glucose homeostasis in obese sedentary men. J Appl Physiol 1996; 81(1): 318-25.
11. van Dam RM, Rimm EB, Willett WC, Stampfer MJ, Hu FB. Dietary patterns and risk for type 2 diabetes mellitus in U.S. men. Ann Intern Med 2002; 136(3): 201-9.
12. Estruch R, Martinez-Gonzalez MA, Corella D, Salas-Salvado J, Ruiz-Gutierrez V, Covas MI, et al. Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. Ann Intern Med 2006; 145(1): 1-11.
13. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 1993; 342(8878): 1007-11.
14. Morand C, Crespy V, Manach C, Besson C, Demigne C, Remesy C. Plasma metabolites of quercetin and their antioxidant properties. Am J Physiol 1998; 275(1 Pt 2): R212-R219.
15. Hollman PC, van Trijp JM, Mengelers MJ, de Vries JH, Katan MB. Bioavailability of the dietary antioxidant flavonol quercetin in man. Cancer Lett 1997; 114(1-2): 139-40.
16. Knekt P, Kumpulainen J, Jarvinen R, Rissanen H, Heliovaara M, Reunanen A, et al. Flavonoid intake and risk of chronic diseases. Am J Clin Nutr 2002; 76(3): 560-8.
17. Erdman JW, Jr., Balentine D, Arab L, Beecher G, Dwyer JT, Folts J, et al. Flavonoids and heart health: proceedings of the ILSI North America Flavonoids Workshop, May 31-June 1, 2005, Washington, DC. J Nutr 2007; 137(3 Suppl 1): 718S-37S.
18. Rivera L, Moron R, Sanchez M, Zarzuelo A, Galisteo M. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Obesity (Silver Spring) 2008; 16(9): 2081-7.
19. Pinho RA, Araujo MC, Ghisi GL, Benetti M. Coronary heart disease, physical exercise and oxidative stress. Arq Bras Cardiol 2010; 94(4): 549-55.[In Portuguese].
20. Boots AW, Drent M, de Boer VC, Bast A, Haenen GR. Quercetin reduces markers of oxidative stress and inflammation in sarcoidosis. Clin Nutr 2011; 30(4): 506-12.
21. Boots AW, Wilms LC, Swennen EL, Kleinjans JC, Bast A, Haenen GR. In vitro and ex vivo anti-inflammatory activity of quercetin in healthy volunteers. Nutrition 2008; 24(7-8): 703-10.
22. Arai Y, Watanabe S, Kimira M, Shimoi K, Mochizuki R, Kinae N. Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol concentration. J Nutr 2000; 130(9): 2243-50.
23. Egert S, Bosy-Westphal A, Seiberl J, Kurbitz C, Settler U, Plachta-Danielzik S, et al. Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a highcardiovascular disease risk phenotype: a doubleblinded, placebo-controlled cross-over study. Br J Nutr 2009; 102(7): 1065-74.
24. Conquer JA, Maiani G, Azzini E, Raguzzini A, Holub BJ. Supplementation with quercetin markedly increases plasma quercetin concentration without effect on selected risk factors for heart disease in healthy subjects. J Nutr 1998; 128(3): 593-7.
25. Juzwiak S, Wojcicki J, Mokrzycki K, Marchlewicz M, Bialecka M, Wenda--Rozewicka L, et al. Effect of quercetin on experimental hyperlipidemia and atherosclerosis in rabbits. Pharmacol Rep 2005; 57(5): 604-9.
26. Kehrer JP. Free radicals as mediators of tissue injury and disease. Crit Rev Toxicol 1993; 23(1): 21-48.
27. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40(4): 405-12.
28. Campbell MJ, Donner A, Klar N. Developments in cluster randomized trials and Statistics in Medicine. Stat Med 2007; 26(1): 2-19.
29. Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12--country reliability and validity. Med Sci Sports Exerc 2003; 35(8): 1381-95.
30. Edwards RL, Lyon T, Litwin SE, Rabovsky A, Symons JD, Jalili T. Quercetin reduces blood pressure in hypertensive subjects. J Nutr 2007; 137(11): 2405-11.
31. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360(9349): 1903-13.
32. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42(6): 1206-52.
33. Hooper L, Kroon PA, Rimm EB, Cohn JS, Harvey I, Le Cornu KA, et al. Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2008; 88(1): 38-50.
34. Nair MP, Mahajan S, Reynolds JL, Aalinkeel R, Nair H, Schwartz SA, et al. The flavonoid quercetin inhibits proinflammatory cytokine (tumor necrosis factor alpha) gene expression in normal peripheral blood mononuclear cells via modulation of the NF-kappa beta system. Clin Vaccine Immunol 2006; 13(3): 319-28.
35. Manach C, Williamson G, Morand C, Scalbert A, Remesy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 2005; 81(1 Suppl): 230S-42S.